Creative Medical Technology Holdings, Inc. develops regenerative medicine and immune-cell therapies as a clinical-stage biotechnology company trading under CELZ. Company news centers on CELZ-201, or olastrocel, an allogeneic/perinatal tissue-derived cell therapy evaluated in the FDA-cleared ADAPT trial for chronic lower back pain associated with degenerative disc disease, and on platform extensions such as Ultrasome for knee osteoarthritis.
Recurring updates also cover WHO International Nonproprietary Name activity for cell-therapy assets, CELZ-101 Treg immunotherapy work, and BioDefense Inc., a wholly owned subsidiary focused on burn pit exposure research using iPSC technology, AI-enabled molecular modeling, and regenerative countermeasure development.
Creative Medical Technology Holdings (OTC: CELZ), a biotechnology company, announced its partnership with Elite Med Listings Inc. on Sept. 16, 2021. This engagement aims to accelerate the adoption of their CaverStem® treatment, which focuses on regenerative medicine. Angela Chatterfield, CEO of Elite Med Listings, expressed confidence in the treatment's efficacy and safety after conducting thorough research. Timothy Warbington, CEO of Creative Medical Technology, looks forward to the collaboration, anticipating a significant business impact.
Creative Medical Technology Holdings, Inc. (CELZ) announced a definitive agreement for a private placement, raising approximately $3,788,000 from accredited institutional investors. The offering includes 15% Original Issue Discount Senior Notes totaling around $4,456,000, maturing on February 11, 2022. Additionally, the company will issue warrants for 157,184,354 shares of common stock, with an initial exercise price of $0.02835 for a five-year period. Roth Capital Partners is the sole placement agent, with the closing expected on August 11, 2021.
Creative Medical Technology Holdings (OTC – CELZ) has announced the launch of its second Regenerative Immunology product, MyeloCelz™, which focuses on utilizing the innate immune system to promote healing. This innovative approach complements the existing ImmCelz™ product, which activates the body’s stem cells primarily through T and B cells. With a focus on personalized therapy, MyeloCelz™ aims to enhance safety and efficacy. The company’s products are backed by comprehensive patent applications, highlighting its commitment to advancing immunotherapy for degenerative conditions.
Creative Medical Technology Holdings (CELZ) has appointed Dr. Courtney Bartlett to lead clinical development for its therapeutic products. Dr. Bartlett brings a decade of experience in cell and gene therapy, having contributed to high-profile stem cell trials. She will prioritize collaborating with the FDA to secure Investigational New Drug application clearance for upcoming stroke treatment trials. The company's existing products, including Caverstem® and StemSpine®, show clinical promise as it aims to expand its pipeline in regenerative medicine.
Creative Medical Technology Holdings (OTC - CELZ) announced its virtual presentation at the World Stem Cell Summit on June 17, 2021, at 12:00pm EST. The session will include a 20-minute presentation followed by a Q&A session moderated by a representative from Noble Capital Markets. Interested participants can register for free at channelchek.com. The presentation will highlight the company's ImmCelz® subsidiary and is part of a broader initiative to foster biomedical research and investment in regenerative medicine.
Creative Medical Technology Holdings (CELZ) has filed a provisional patent application for its ImmCelz® personalized cell therapy product, demonstrating its potential to suppress autoimmune diabetes. Recent experiments revealed that ImmCelz® enhances the effects of BCG and GM-CSF in preventing diabetes by increasing myeloid suppressor cell activity. The company's focus on innovative immunological pathways is expected to strengthen its intellectual property during the FDA approval process. ImmCelz® has also shown promising results in preclinical models related to various medical conditions.
Creative Medical Technology Holdings (CELZ) announced promising preclinical data suggesting ImmCelz® could treat Parkinson's Disease. Using the MPTP mouse model, ImmCelz® inhibited Parkinsonism-like behavior and protected dopamine cells, enhancing interleukin-10 levels. With over 1 million Parkinson's patients in the USA, this innovation represents a significant market opportunity. The company aims to advance its lead indication, stroke, and address FDA comments before initiating human trials. Overall, this expansion could bolster CELZ's product pipeline in regenerative immunotherapy.
Creative Medical Technology Holdings announced the recruitment of Dr. Camillo Ricordi to its Scientific Advisory Board. Dr. Ricordi will work alongside esteemed advisors to advance the ImmCelz® Regenerative Immunotherapy platform, currently seeking FDA clearance for IND # 27375 to treat stroke. The company has already made strides with its CaverStem® Procedure for erectile dysfunction and has proof of concept for its StemSpine® and OvaStem® treatments. Dr. Ricordi is recognized for his pioneering work in regenerative medicine and stem cell therapies.
Creative Medical Technology Holdings (CELZ) announced receipt of detailed correspondence from the FDA regarding IND #27375 for its ImmCelz® regenerative immunotherapy targeting stroke treatment. This innovative therapy employs a patient's own reprogrammed blood cells, demonstrating effectiveness in animal models for various conditions, including heart and kidney failure. The company's leadership expressed gratitude for the FDA's constructive feedback, essential for the IND proposal's progression. This marks a significant step in their journey towards obtaining regulatory approval for a pioneering treatment.
Creative Medical Technology Holdings (OTC: CELZ) plans to launch Virtual Physician™, a telehealth platform for regenerative medicine, this summer. The platform aims to educate, recruit, and retain patients for their proprietary procedures, such as CaverStem® for erectile dysfunction and FemCelz® for vaginal rejuvenation. As additional products like StemSpine® are commercialized, the platform will expand. The initiative is expected to create shareholder value through a Management Service Organization model, royalties from product promotions, and direct sales of ancillary products.